EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden
The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described. Demographics, core set data, EQ-5D utility, and treatment characteristics for patients with established RA, receiving biologics in southern Sweden from January 2006 to March 2014, were retrieved from observational databases. Theoretical, UK, and experience-based, SE, EQ-5D mean utilities were plotted... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Reihe/Periodikum: | Arthritis research & therapy |
| Verlag/Hrsg.: |
London,
BioMed Central
|
| Sprache: | Englisch |
| ISSN: | 1478-6354 |
| Permalink: | https://search.fid-benelux.de/Record/olc-benelux-1974274004 |
| Datenquelle: | Online Contents Benelux; Originalkatalog |
| Powered By: | Verbundzentrale des GBV (VZG) |
